why choose us

First received: January 04, 2023

Clinical Trial: Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Anatomic Stage III Breast Cancer AJCC v8

Study Type: INTERVENTIONAL


Official Title: Phase I Study Targeting DNA Methyltransferases in Metastatic Triple-Negative Breast Cancer

Brief Summary: This phase I trial tests the safety, side effects, and best dose of ASTX727 when given in combination with a usual approach of treatment with paclitaxel and pembrolizumab in patients with triple-negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic).The usual approach is defined as care most people get for this type of cancer.The usual approach for patients with metastatic triple negative breast cancer who are not in a study is chemotherapy with…

Read more